Cargando…
Greater Combined Reductions of HbA(1c) ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
INTRODUCTION: A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA(1c) (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators. METHODS: In the PIONEER trials, peopl...
Autores principales: | Dungan, Kathleen M., Bardtrum, Lars, Christiansen, Erik, Eliasson, Johanna, Mellbin, Linda, Woo, Vincent C., Vilsbøll, Tina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299987/ https://www.ncbi.nlm.nih.gov/pubmed/37256503 http://dx.doi.org/10.1007/s13300-023-01413-5 |
Ejemplares similares
-
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021) -
WWW-SMI-Interface 1.0 and SMI-Analyzer 1.0
por: Glege, F
Publicado: (1999) -
Indico 1.0
por: Lopez, J B Gonzalez, et al.
Publicado: (2014) -
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023) -
Electronic, mechanical and piezoelectric properties of glass-like complex Na(2)Si(1−x)Ge(x)O(3) (x = 0.0, 0.25, 0.50, 0.75, 1.0)
por: Zosiamliana, R., et al.
Publicado: (2022)